The treatments for ovarian cancer recurrence, mainly including surgery, chemicals and targeted drugs, need to be immediately consulted in the hospital and chosen according to the patient’s specific situation. 1. Surgical treatment has limited effects and should be performed after comprehensive and careful evaluation. Its main role includes relieving complications and isolating recurrent foci. 2. Chemotherapy is the main means to treat recurrent ovarian cancer, and the choice of drugs should be based on the comprehensive consideration of the first-line treatment plan, efficacy, toxicity and side effects as well as the recurrence time of the tumor, and there are the following treatment principles to choose the treatment plan, which should be carried out under the guidance of doctors. If the first-line treatment does not contain platinum, platinum-based combination chemotherapy should be chosen; if the first-line drugs are platinum-based drugs, after the end of chemotherapy to the time of tumor recurrence >6 months, platinum-based combination chemotherapy can be chosen; if the platinum-free interval is <6 months, or if the first-line chemotherapy does not achieve the effect of complete remission, the second-line drugs should be chosen, for example, topotecan. 3. Targeted therapy, such as poly(adenosine diphosphate ribose polymerase) (PARP) inhibitor is used for the maintenance therapy of second-line chemotherapy for Birmingham recurrence with BRCA1/BRCA2 gene mutation. Once recurrent ovarian cancer is identified, the prognosis is poor, so the quality of life of patients should be prioritized, the doctor’s advice should be heeded to choose the appropriate treatment plan, and drugs need to be reasonably applied according to the doctor’s prescription.